<ѻýҕl>Enzalutamide Rechallenge Yields Small PFS Boost in Metastatic Prostate Cancerѻýҕl> Docetaxel-enzalutamide regimen may offer another option for men who progressed on AR inhibitor Feb 18, 2022
<ѻýҕl>Two PARP Inhibitors Impress as First-Line Add-Ons in mCRPCѻýҕl> In one case, rPFS benefit was seen regardless of HRR mutational status Feb 18, 2022
<ѻýҕl>Ablating High-Grade Anal Lesions Thwarts Progression to Cancerѻýҕl> Screening followed by aggressive therapy shows benefit in phase III ANCHOR study Feb 17, 2022
<ѻýҕl>Darolutamide Improves OS in Metastatic Prostate Cancerѻýҕl> The AR inhibitor plus standard therapy led to a 32% reduced risk of death versus placebo Feb 17, 2022
<ѻýҕl>Early Clinical Activity With CDK4/6 Inhibitor in Pretreated Mesotheliomaѻýҕl> Disease control in 54% of patients in first clinical evaluation of abemaciclib Feb 17, 2022
<ѻýҕl>Sotorasib Impresses in Advanced Pancreatic Cancerѻýҕl> ORR of 21% in heavily pretreated patients with a KRAS G12C mutation Feb 16, 2022
<ѻýҕl>Third Person 'Cured' of HIV via Transplantѻýҕl> U.S. woman with leukemia gets cord blood resistant to HIV Feb 16, 2022
<ѻýҕl>Long-Term Survival Benefit in NSCLC With Another Anti-PD-1/L1 Drugѻýҕl> Significant improvements in OS, PFS with durvalumab after CRT for unresectable disease Feb 15, 2022
<ѻýҕl>Women More Likely to Experience Severe Toxicity of Cancer Treatmentsѻýҕl> Increased risk was particularly pronounced among those receiving immunotherapy Feb 14, 2022
<ѻýҕl>Pembrolizumab Shows Promise in Advanced Anal Cancerѻýҕl> PD-1 inhibitor may be an option for those who have no options Feb 11, 2022
<ѻýҕl>Active Cellular Immunotherapy Disappoints in Metastatic Prostate Cancerѻýҕl> In combination with chemotherapy, no OS benefit seen with DCVAC/PCa over placebo Feb 10, 2022
<ѻýҕl>Illusionist Criss Angel's Son's Acute Leukemiaѻýҕl> Famed magician speaks about the long battle Feb 09, 2022
<ѻýҕl>Uterine Cancer Mortality Now Neck and Neck With Ovarian Cancerѻýҕl> Advances in ovarian cancer, stagnation in uterine cancer, and "alarming" racial disparity Feb 09, 2022
<ѻýҕl>Did Improved Treatment for Cervical Abnormalities Affect Birth Outcomes?ѻýҕl> Swedish data found risks for adverse outcomes remain higher, but declined over time Feb 07, 2022
<ѻýҕl>Dear Blood Donors, You've Given Me the Gift of Lifeѻýҕl> I offer my gratitude through acceptance, acknowledgement, and reflection Feb 06, 2022
<ѻýҕl>FDA Concerned About Safety of Lymphoma Drugѻýҕl> Hint of excess mortality in trial of umbralisib/ublituximab prompts public notice Feb 03, 2022
<ѻýҕl>Genetic Role of Alcohol-Cancer Link Strengthenedѻýҕl> In study from China, two common variants associated with lower risk of cancer in men Feb 01, 2022
<ѻýҕl>When Strangers Deliver Bad News to Patientsѻýҕl> All too often, I end up giving prognoses to patients I barely know Jan 31, 2022
<ѻýҕl>Dual HER2 Therapy Active in Previously Treated Lung Cancerѻýҕl> Disease control in 87% of HER2-mutant NSCLC treated with trastuzumab, pertuzumab, docetaxel Jan 27, 2022
<ѻýҕl>An 'Intriguing Failure' in Advanced, Pre-Treated GISTѻýҕl> Second-line ripretinib unable to best sunitinib, but still had meaningful clinical activity Jan 26, 2022
<ѻýҕl>Trial Data Confirm Heightened Risks With JAK Inhibitorѻýҕl> May help patients and clinicians better weigh benefit against adverse effects Jan 26, 2022
<ѻýҕl>Paclitaxel-Carboplatin Established as Standard of Care for Uterine Carcinosarcomaѻýҕl> Median OS and PFS improved versus paclitaxel-ifosfamide Jan 25, 2022
<ѻýҕl>GICS Roundup: PD-1 Inhibitor Yields 100% Response Rate in dMMR Rectal Cancerѻýҕl> Plus: Promising activity in BRAF-mutant CRC, L-asparaginase drug falls short in pancreatic cancer Jan 24, 2022
<ѻýҕl>Adagrasib Promising in KRAS-Mutant GI Cancersѻýҕl> The KRAS G12C inhibitor showed a disease control rate of 100% in small study Jan 24, 2022
<ѻýҕl>Survival Bump in Biliary Cancer With Immunotherapy Plus Chemotherapyѻýҕl> Adding durvalumab boosts OS by 1.3 months, first survival improvement in a decade Jan 23, 2022
<ѻýҕl>Immunotherapy Not Additive to Standard of Care for Untreated Metastatic CRCѻýҕl> No difference in survival outcomes with add-on nivolumab to chemo, bevacizumab Jan 23, 2022
<ѻýҕl>Potential New First-Line Options for Unresectable Hepatocellular Carcinomaѻýҕl> Tremelimumab-durvalumab improves OS, single-agent durvalumab non-inferior to sorafenib Jan 22, 2022
<ѻýҕl>Pre-Op Immunotherapy Combo Makes Headway in Select Gastric Cancersѻýҕl> Plus, novel bispecific antibody tested as first-line therapy for advanced gastric/GEJ cancer Jan 21, 2022
<ѻýҕl>More Data for Upfront PD-1 Inhibition in Gastric, Esophageal Cancerѻýҕl> Updates from two landmark trials show consistent benefits across subgroups, PD-L1 expression Jan 21, 2022
<ѻýҕl>We've Never Really Understood the Prostateѻýҕl> Wolinsky reviews Ericka Johnson's new book, A Cultural Biography of the Prostate Jan 19, 2022
<ѻýҕl>Growing Controversy Over 'Skinny' Labeling for Generic Drugsѻýҕl> What's at stake in legal battles over patent-avoiding approval pathway for generics Jan 17, 2022
<ѻýҕl>Active Surveillance for Melanoma Meets Reality of Loss to Follow-Upѻýҕl> More than a third of patients lost to follow-up in "real-world" experience Jan 10, 2022
<ѻýҕl>Earlier Colorectal Screening Bolstered by Real-World Dataѻýҕl> Researchers of a national registry study say "45 is now the new 50" Jan 10, 2022
<ѻýҕl>Melanoma Patient on Immunotherapy Develops Severe Dermatitisѻýҕl> Clinicians faced with presumed dermatologic AEs urged to consider all differentials Jan 10, 2022
<ѻýҕl>Older Patients With Low-Risk DCIS May Not Benefit From Surgery, Radiationѻýҕl> Low rate of invasive recurrence, benefits of surgery and RT limited to patients under 70 Jan 05, 2022
<ѻýҕl>Finally, a 'New Standard' for Severe Aplastic Anemiaѻýҕl> After 3 decades of failures, RACE trial shows superiority of new first-line regimen Jan 05, 2022
<ѻýҕl>Myeloma at Younger Age Shortens Lifespan Despite Lengthy Overall Survivalѻýҕl> Disease characteristics, prognostic factors similar to those of older patients Jan 04, 2022
<ѻýҕl>In Early Prostate Cancer, Black Men Do Better With Radiotherapy Than White Menѻýҕl> "Unexpected" finding holds even though Black men are more likely to have high-risk features Dec 29, 2021
<ѻýҕl>Living History: 50 Years After the Birth of National Cancer Centersѻýҕl> New book examines the progress 50 years following the National Cancer Act of 1971 Dec 22, 2021